1.Use of granulocyte-macropharge colony stimulating factor (GM-CSF) in azathioprine-induced leukopenic renal transplant recipients.
Dong Chan JIN ; Young Suk YOON ; Suk Young KIM ; Eui Jin CHOI ; Byung Kee BANG
Korean Journal of Nephrology 1993;12(4):674-676
No abstract available.
Colony-Stimulating Factors*
;
Transplantation*
2.Clinical application of granulouyte colony-stimulating factor and granlocyte, Macrophage colomy-stimulating factor.
Korean Journal of Medicine 1999;57(4):442-448
No abstract available.
Colony-Stimulating Factors*
;
Macrophages*
3.Colony Stimulating Factor 3 Mutations and Myeloid Malignancies.
Acta Academiae Medicinae Sinicae 2016;38(1):103-107
Granulocyte colony stimulating factor (G-CSF) plays a major role in the proliferation, differentiation, and activation of neutrophil cell line hematopoietic cells. G-CSF exert the function depending on its binding to colony-stimulating factor 3 receptor (CSF3R), a homo-dimer receptor located on the surface of effector cells. Some recent studies have demonstrated that CSF3R mutations play a significant role in many diseases. Some of the hematopoietic diseases, especially myeloid malignancies (e.g. chronic neutrophilic leukemia) are related to the presence of various CSF3R mutations, which leads to abnormal G-CSF signal pathways. Also, the downstream kinases can be the treatment targets for these diseases. This review summarizes CSF3R mutations, mechanisms of mutations, and their contributions to the myeloid malignancies, with an attempt to further reveal the pathogenesis of myeloid malignancies, inform the diagnosis and clinical treatment of the myeloid malignancies, and provide clues for the research and development of new molecular target drugs.
Colony-Stimulating Factors
;
Hematologic Neoplasms
;
Humans
;
Mutation
;
Myeloid Cells
;
Receptors, Colony-Stimulating Factor
;
Signal Transduction
4.The Effect of Granulocyte Colony Stimulating Factor and Granulocyte Macrophage Colony Stimulating Factor on the Preimplantation Development and Implantation in Mouse Embryos.
Chung Hoon KIM ; Eun Ju PARK ; Jong Yoon HWANG ; Seok Ho HONG ; Sung Hoon KIM ; Hee Dong CHAE ; Byung Moon KANG
Korean Journal of Obstetrics and Gynecology 2002;45(1):126-132
OBJECTIVE: To investigate the influence of granulocyte colony stimulating factor (G-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) on preimplantation development and implantation in mouse embryos. MATERIAL AND METHODS: Eight-cell stage mouse embryos were cultured for 96 hours with G-CSF or GM-CSF at concentrations of 10 pg/ml, 100 pg/ml, 1 ng/ml and 10 ng/ml. Embryos not treated with G-CSF or GM-CSF were served as control. The percentages of embryos which developed to expanded, hatched blastocyst stage and in vitro implantation at 96 hours were determined. Results were analyzed with Kolmogorov-Smirnov test and analysis of variance (ANOVA). The statistical significance was defined as p<0.05. RESULTS: The percentages of fully expanded blastocysts in all G-CSF and GM-CSF treatment groups were not significantly different from the control. The percentages of hatched blastocysts were significantly higher in 100 pg/ml and 10 ng/ml of G-CSF treatment group compared to the control (p<0.05, p<0.05, respectively). The percentages of hatched blastocysts were significantly lower in 1 ng/ml of GM-CSF treatment group compared to the control, 10 pg/ml, and 100 pg/ml of GM-CSF treatment group (p<0.05, p<0.05, p<0.05, respectively), and the percentages of hatched blastocysts were also significantly lower in 10 ng/ml of GM-CSF treatment group compared to the control and 100 pg/ml of GM-CSF treatment group (p<0.05, p<0.05, respectively). The percentages of implanted blastocysts in vitro were significantly higher following incubation with all concentrations of G-CSF compared to the control and, especially in 100 pg/ml and 10 ng/ml of G-CSF treatment groups compared to the control and other treatment groups. The percentages of implanted blastocysts in vitro were significantly higher in 10 pg/ml of GM-CSF treatment group than the control and 100 pg/ml of GM-CSF treatment groups (p<0.05, p<0.05, respectively). CONCLUSION: G-CSF and GM-CSF might influence on embryonic development and implantation in mouse embryos.
Animals
;
Blastocyst
;
Colony-Stimulating Factors*
;
Embryonic Development
;
Embryonic Structures*
;
Female
;
Granulocyte Colony-Stimulating Factor
;
Granulocyte-Macrophage Colony-Stimulating Factor*
;
Granulocytes*
;
Mice*
;
Pregnancy
5.Effect of GM-CSF to the M-VAC Chemotherapy Induced Leukopenia in Patients with Urothelial Cancer.
Jong Bo CHOI ; Dong Sun KIM ; Jae Heung CHO
Korean Journal of Urology 1994;35(2):151-155
Granulocyte macrophage-colony stimulating factor (GM-CSF) occupies a central position in the regulation of hematopoietic responses. GM-CSF not only signals proliferations of granulocyte-macrophage but also drives these cells into differentiation and activates mature cells of the GM-CSF sensitive lineage. Myelosuppression that is induced by M-VAC (methotrexate, vinblastine, doxorubicin, cisplatinum) chemotherapy brings many problems in successful treatment such as sepsis, dose reduction, delaying the schedule. Granulocyte-macrophage colony stimulating factor is introduced hopefully as a new solution for these problems. So we evaluated the efficacy and safety of GM-CSF in leukopenia induced by M-VAC chemotherapy in patients with urothelial cancer. GM-CSF was administered at 200ug subcutaneously in 10 M-VAC cycles of 6 patients on 5th and 6th day after M-VAC therapy. Sixteen cycles, by which only M-VAC chemotherapy was administered without GM-CSF. of the other 6 patients served as control group. Mean white blood cell count in peripheral blood at M-VAC 2nd day and 15th day was 5,630/mm3 and 4,240/mm3 in GM-CSF administered cycles, 6,58l/mm3and 3,613/mm3 in non GM-CSF administered cycles. There was no delayed cycle in administration of MTX and vinblastine at M-VAC 15th day in the cycles with GM-CSF. There was no significant side effects caused by GM- CSF. The result indicates that GM-CSF can be used safely and effectively against leukopenia after M-VAC chemotherapy of urothelial cancer.
Appointments and Schedules
;
Colony-Stimulating Factors
;
Doxorubicin
;
Drug Therapy*
;
Granulocyte-Macrophage Colony-Stimulating Factor*
;
Granulocytes
;
Humans
;
Leukocyte Count
;
Leukopenia*
;
Sepsis
;
Vinblastine
6.Application of Apoptogenic Pretreatment to Enhance Anti-tumor Immunity of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)-secreting CT26 Tumor Cells.
Do Youn JUN ; Elizabeth M JAFFEE ; Young Ho KIM
Immune Network 2005;5(2):110-116
BACKGROUND: As an attempt to develop a strategy to improve the protective immune response to GM-CSF-secreting CT26 (GM-CSF/CT26) tumor vaccine, we have investigated whether the apoptogenic treatment of GM-CSF/CT26 prior to vaccination enhances the induction of anti-tumor immune response in mouse model. METHODS: A carcinogen- induced mouse colorectal tumor, CT26 was transfected with GM-CSF gene using a retroviral vector to generate GM-CSF-secreting CT26 (CT26/GM-CSF). The CT26/GM-CSF was treated with gamma-irradiation or mitomycin C to induce apoptosis and vaccinated into BALB/c mice. After 7 days, the mice were injected with a lethal dose of challenge live CT26 cells to examine the protective effect of tumor vaccination in vivo. RESULTS: Although both apoptotic and necrotic CT26/GM-CSF vaccines were able to enhance anti-tumor immune response, apoptotic CT26/GM-CSF induced by pretreatment with gamma-irradiation (50,000 rads) was the most potent in generating the anti-tumor immunity, and thus 100% of mice vaccinated with the apoptotic cells remained tumor free for more than 60 days after tumor challenge. CONCLUSION: Apoptogenic pretreatment of GM-CSF-secreting CT26 tumor vaccine by gamma-irradiation (50,000 rads) resulted in a significant enhancement in inducing the protective anti-tumor immunity. A rapid induction of apoptosis of CT26/GM-CSF tumor vaccine at the vaccine site might be critical for the enhancement in anti-tumor immune response to tumor vaccine.
Animals
;
Apoptosis
;
Colony-Stimulating Factors*
;
Colorectal Neoplasms
;
Granulocyte-Macrophage Colony-Stimulating Factor
;
Mice
;
Mitomycin
;
Vaccination
;
Vaccines
;
Zidovudine
7.Effect of Granulocyte-macrophage Colony-stimulating Factor in Neonatal Infection.
Journal of the Korean Pediatric Society 2000;43(12):1552-1557
PURPOSE: Neutrophils are central to the defences against bacterial infection, and in neonates the number of neutrophils are decreased due to inhibited production and phagocytic function. This induces high mortality rates in infants suffering from neonatal sepsis. Exogenous GM-CSF can increase the number of neutrophils and improve the phagocytic function. To establish the most cost effective dose of exogenous granulocyte-macrophage colony-stimulating factor in infected neonates, we divided infected patients into two groups. The serum level of granulocyte-macrophage colony stimulating factor, white blood cell count and absolute granulocyte count were compared. METHODS: This study included 22 infants with infection, admitted to the neonatal intensive care unit of Chungnam National University Hospital, between February 1998 and September 1999. Infected infants were divided into two treatment groups with exogenous GM-CSF 3 microgram/kg/day & 10 microgram/kg/day. The total WBC count, the absolute granulocyte count and the serum GM-CSF concentration of peripheral blood before use of GM-CSF, and those of 2nd, 5th and 7th day after use were compared. RESULTS: In 3 microgram/kg/day group, WBC count and the absolute granulocyte count and the serum GM-CSF concentration reached a peak after the 2nd injection of GM-CSF. In 10 microgram/kg/day group, the WBC count and the absolute granulocyte count increased gradually until 7th day. There was tendency for the total WBC counts, the absolute granulocyte count and the serum GM-CSF concentration of peripheral blood in 10 microgram/kg group to increase more than those of 3 microgram/kg group, after exogenous GM-CSF treatment. CONCLUSION: In neonates, we propose the exogenous GM-CSF treatment 10 microgram/kg/day as being more effective than 3 microgram/kg/day protocol, which is one of the safest and most effective methods to increase the total WBC count, the absolute granulocyte count and the serum GM-CSF concentration of peripheral blood.
Bacterial Infections
;
Chungcheongnam-do
;
Colony-Stimulating Factors
;
Granulocyte-Macrophage Colony-Stimulating Factor*
;
Granulocytes
;
Humans
;
Infant
;
Infant, Newborn
;
Intensive Care, Neonatal
;
Leukocyte Count
;
Leukocytes
;
Mortality
;
Neutrophils
;
Sepsis
8.A Case of Idiopathic Pulmonary Alveolar Proteinosis Treated with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) after Partial Response to Whole Lung Lavage.
Jun Whi SONG ; Sun Hyo PARK ; Kyung Woo KANG
Tuberculosis and Respiratory Diseases 2009;67(6):569-573
Idiopathic pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by surfactant component accumulation in the alveolar space. Idiopathic PAP has recently been recognized as a autoimmune disease of impaired alveolar macrophage function caused by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF). While whole lung lavage has been the standard treatment, not every patient shows a complete response. Subcutaneous injection or inhalation of GM-CSF is another promising treatment option for PAP. A 45-year-old patient visited our hospital for dyspnea, he was diagnosed as PAP and underwent whole lung lavage. Eighteen months later, the patient had not achieved complete remission in despite of initial response. After then he was administered with GM-CSF (5 microgram/kg/day, subcutaneous injection) for fivetimes a week during 2 months. Nine months later, the abnormal shadows in high-resolution computed tomography (HRCT) decreased and the patient fully recovered in forced vital capacity. After 60 months, the HRCT scan showed complete remission of PAP.
Autoantibodies
;
Autoimmune Diseases
;
Bronchoalveolar Lavage
;
Colony-Stimulating Factors
;
Dyspnea
;
Granulocyte-Macrophage Colony-Stimulating Factor
;
Humans
;
Inhalation
;
Injections, Subcutaneous
;
Lung
;
Macrophages, Alveolar
;
Middle Aged
;
Pulmonary Alveolar Proteinosis
;
Vital Capacity
9.The Effect of GM-CSF Supplementation in Culture Medium in the Human IVF Programs.
Won Il PARK ; Hyuck Chan KWON ; Dong Hoon KIM ; Hee Kyoo KANG ; Myo Kyung KIM ; Hoi Chang LEE ; Ji Hak JUNG ; Myong Seop LEE ; Ho Joon LEE
Korean Journal of Fertility and Sterility 2001;28(2):161-168
OBJECTIVE: Granulocyte-macrophage colony stimulating factors known to be secreted in murine and human reproductive tract. The development of human, bovine and murine embryos could be promoted by addition of GM-CSF in culture medium. However, the pregnancy and implantation rate of embryos cultured in GM-CSF have not been evaluated. The aim of this study was to assess the effect of GM-CSF in embryo development, pregnancy and implantation rate. METHODS: A total of 191 IVF cycles were divided into control and GM-CSF supplement group (control =96, GM-CSF=95). The embryos were cultured for three day with or without 2 ng/ml of recombinant human GM-CSF. The quality of embryo, developmental velocity, pregnancy and implantation rates were compared. RESULTS: There was no difference in age, number of gonadotropin ampules used, number of oocytes and fertilization. The number of ICSI cycle was higher in GM-CSF group. In GM-CSF group, G-1 grade embryos were the highest in proportion (56.4%), while G-2 grade embryos were highest (44.3%) in control group. The developmental velocity of embryos were not different between GM-CSF and control group. The pregnancy and implantation rates were significantly higher in GM-CSF group than control (47.4% vs. 33.3%, 17.0% vs. 11.1% respectively). CONCLUSION: By adding GM-CSF in culture medium, the quality of embryo, pregnancy and implantation rate could be improved.
Colony-Stimulating Factors
;
Embryonic Development
;
Embryonic Structures
;
Female
;
Fertilization
;
Gonadotropins
;
Granulocyte-Macrophage Colony-Stimulating Factor*
;
Humans*
;
Oocytes
;
Pregnancy
;
Sperm Injections, Intracytoplasmic
10.A Case of Pulmonary Alveolar Proteinosis that Improved with GM-CSF Inhalation Therapy.
Bok Soon CHANG ; Jungwon NOH ; Chang Soo OK ; Ga Yeon LEE ; Seo Young SOHN ; Sunha BAHNG ; Man Pyo CHUNG
Korean Journal of Medicine 2011;80(5):588-594
Pulmonary alveolar proteinosis (PAP) is a rare condition that is treated using whole lung lavage. A recent study suggested that granulocyte-macrophage colony stimulating factor (GM-CSF) plays roles in both the pathogenesis and treatment of PAP. We present a 69-year-old man with PAP who deteriorated despite bilateral whole lung lavage; that said, his symptoms, chest X-ray findings, and pulmonary function test improved after GM-CSF inhalation therapy over 12 months. GM-CSF therapy is an effective treatment modality for PAP.
Aged
;
Bronchoalveolar Lavage
;
Colony-Stimulating Factors
;
Granulocyte-Macrophage Colony-Stimulating Factor
;
Humans
;
Inhalation
;
Lung
;
Pulmonary Alveolar Proteinosis
;
Respiratory Function Tests
;
Respiratory Therapy
;
Thorax